Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RSV
Biotech
Layoffs at Meissa Vaccines as biotech's future lies in limbo
Meissa Vaccines is putting its portfolio on hold and laying off staff due to the current fundraising environment, the company told Fierce Biotech.
Gabrielle Masson
Mar 5, 2024 10:25am
Investors home in on Moderna's RSV, CMV prospects
Feb 22, 2024 10:09am
CRO hVIVO reels in £16.8M clinical trial deal for RSV drug
Dec 13, 2023 11:28am
Enanta halts work on joint hMPV-RSV drug to extend cash to 2027
Nov 21, 2023 8:30am
Moderna could be open to out-licensing if sales struggle: Bancel
Nov 2, 2023 11:09am
Bavarian Nordic crashes out of RSV race after phase 3 trial
Jul 24, 2023 5:00am